Balaji Prasad
Stock Analyst at Barclays
(2.80)
# 1,500
Out of 5,182 analysts
147
Total ratings
49.19%
Success rate
4.74%
Average return
Main Sectors:
Stocks Rated by Balaji Prasad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EOLS Evolus | Maintains: Overweight | $22 → $25 | $5.27 | +374.38% | 8 | Mar 5, 2025 | |
| AMRX Amneal Pharmaceuticals | Maintains: Overweight | $10 → $11 | $12.74 | -13.62% | 5 | Mar 3, 2025 | |
| PCRX Pacira BioSciences | Maintains: Overweight | $17 → $24 | $25.41 | -5.55% | 9 | Feb 28, 2025 | |
| VTRS Viatris | Maintains: Underweight | $12 → $9 | $14.82 | -39.27% | 8 | Feb 28, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $190 → $200 | $203.98 | -1.95% | 10 | Feb 27, 2025 | |
| ELAN Elanco Animal Health | Maintains: Overweight | $20 → $19 | $22.15 | -14.22% | 13 | Feb 26, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Overweight | $62 → $60 | $62.09 | -3.37% | 5 | Feb 26, 2025 | |
| ZTS Zoetis | Maintains: Overweight | $242 → $244 | $116.65 | +109.17% | 16 | Feb 14, 2025 | |
| OGN Organon & Co. | Maintains: Overweight | $26 → $24 | $13.32 | +80.18% | 2 | Feb 14, 2025 | |
| PAHC Phibro Animal Health | Maintains: Underweight | $20 → $22 | $54.29 | -59.48% | 8 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $481 → $520 | $568.30 | -8.50% | 9 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $26 | $31.62 | -17.77% | 12 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $150 → $160 | $232.32 | -31.13% | 15 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $17 | $14.03 | +21.17% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $18 | $3.52 | +411.36% | 5 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2.5 → $10 | $4.43 | +125.73% | 2 | Oct 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $7 | $1.77 | +295.48% | 7 | Oct 23, 2023 |
Evolus
Mar 5, 2025
Maintains: Overweight
Price Target: $22 → $25
Current: $5.27
Upside: +374.38%
Amneal Pharmaceuticals
Mar 3, 2025
Maintains: Overweight
Price Target: $10 → $11
Current: $12.74
Upside: -13.62%
Pacira BioSciences
Feb 28, 2025
Maintains: Overweight
Price Target: $17 → $24
Current: $25.41
Upside: -5.55%
Viatris
Feb 28, 2025
Maintains: Underweight
Price Target: $12 → $9
Current: $14.82
Upside: -39.27%
Jazz Pharmaceuticals
Feb 27, 2025
Maintains: Overweight
Price Target: $190 → $200
Current: $203.98
Upside: -1.95%
Elanco Animal Health
Feb 26, 2025
Maintains: Overweight
Price Target: $20 → $19
Current: $22.15
Upside: -14.22%
Tarsus Pharmaceuticals
Feb 26, 2025
Maintains: Overweight
Price Target: $62 → $60
Current: $62.09
Upside: -3.37%
Zoetis
Feb 14, 2025
Maintains: Overweight
Price Target: $242 → $244
Current: $116.65
Upside: +109.17%
Organon & Co.
Feb 14, 2025
Maintains: Overweight
Price Target: $26 → $24
Current: $13.32
Upside: +80.18%
Phibro Animal Health
Feb 10, 2025
Maintains: Underweight
Price Target: $20 → $22
Current: $54.29
Upside: -59.48%
Feb 4, 2025
Maintains: Overweight
Price Target: $481 → $520
Current: $568.30
Upside: -8.50%
Jan 30, 2025
Maintains: Overweight
Price Target: $28 → $26
Current: $31.62
Upside: -17.77%
Dec 16, 2024
Maintains: Overweight
Price Target: $150 → $160
Current: $232.32
Upside: -31.13%
Nov 6, 2024
Maintains: Overweight
Price Target: $17 → $17
Current: $14.03
Upside: +21.17%
Jul 25, 2024
Maintains: Overweight
Price Target: $22 → $18
Current: $3.52
Upside: +411.36%
Oct 23, 2023
Maintains: Equal-Weight
Price Target: $2.5 → $10
Current: $4.43
Upside: +125.73%
Oct 23, 2023
Maintains: Overweight
Price Target: $8 → $7
Current: $1.77
Upside: +295.48%